Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1–Independent Manner
Open Access
- 8 December 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 11 (2) , 241-260
Abstract
CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6) is known to be a regulator of membranal programmed death ligand 1 (PD-L1) stability and a factor associated with malignancy progression, but the effects and mechanisms of CMTM6 on tumor growth, as well as its potential as a target for therapy, are still largely unknown. Here, we show that CMTM6 expression increased with tumor progression in both patients and mice. Ablation of CMTM6 significantly reduced human and murine tumor growth in a manner dependent on T-cell immunity. Tumor CMTM6 suppression broke resistance to immune-checkpoint inhibitors and remodeled the tumor immune microenvironment, as specific antitumor cytotoxicity was enhanced and contributed primarily to tumor inhibition. Without the PD-1/PD-L1 axis, CMTM6 suppression still significantly dampened tumor growth dependent on cytotoxic cells. Furthermore, we identified that CMTM6 was widely expressed on immune cells. T-cell CMTM6 levels increased with sustained immune activation and intratumoral immune exhaustion and affected T cell–intrinsic PD-L1 levels. Host CMTM6 knockout significantly restrained tumor growth in a manner dependent on CD8+ T cells and not entirely dependent on PD-L1. Thus, we developed and evaluated the antitumor efficacy of CMTM6-targeting adeno-associated virus (AAV), which effectively mobilized antitumor immunity and could be combined with various antitumor drugs. Our findings reveal that both tumor and host CMTM6 are involved in antitumor immunity with or without the PD-1/PD-L1 axis and that gene therapy targeting CMTM6 is a promising strategy for cancer immunotherapy.Keywords
All Related Versions
Funding Information
- Foundation of Shanghai Science and Technology Committee (No.22S11902100)
- Zhongshan Municipal Bureau of Science and Technology (No.2020SYF08)
- Department of Science and Technology of Guangdong Province (No.2019B090904008)
- Department of Science and Technology of Guangdong Province (No.2021B0909050003)
- Strategic Priority Research Program of the Chinese Academy of Sciences (No. XDA 12050305)
This publication has 56 references indexed in Scilit:
- CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunityNature, 2017
- GEPIA: a web server for cancer and normal gene expression profiling and interactive analysesNucleic Acids Research, 2017
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialThe Lancet, 2016
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunityNature, 2015
- Tissue-based map of the human proteomeScience, 2015
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature, 2014
- A Critical Role for the Regulated Wnt–Myc Pathway in Naive T Cell SurvivalThe Journal of Immunology, 2014
- Regulation of EGF receptor signaling by the MARVEL domain‐containing protein CKLFSF8FEBS Letters, 2005
- Identification of eight genes encoding chemokine-like factor superfamily members 1–8 (CKLFSF1–8) by in silico cloning and experimental validationGenomics, 2003
- MARVEL: a conserved domain involved in membrane apposition eventsTrends in Biochemical Sciences, 2002